913722-72-2

Upstream product

• 1057086-30-2 benzyl (S)-1-(3-((S)-1-aminoethyl)phenyl)propan-2-ylcarbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 501-53-1 benzyl chloroformate 
• 107484-93-5 C₁₀H₁₁BrMgO₂ 
• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 6429-44-3 (S)-(-)-N-(benzyloxycarbonyl)alaninol 
• 39172-32-2 2-(3-bromophenyl)-2-methyl-[1,3]dioxolane 
• 946088-68-2 benzyl 2-methylaziridine-1-carboxylate 
• 1057086-31-3 benzyl (S)-1-(3-((S)-1-azidoethyl)phenyl)propan-2-ylcarbamate 
• 946088-73-9 Benzyl (S)-1-(3-((R)-1-hydroxyethyl)phenyl)propan-2-ylcarbamate 
• 881206-91-3 (S)-benzyl 1-(3-acetylphenyl)propan-2-ylcarbamate 
• 872059-44-4 [2-(3-bromo-phenyl)-1S-methyl-ethyl]-carbamic acid benzyl ester 
• 849831-52-3 3-(3-bromophenyl)-2-methylpropionic acid 
• 100-51-6 benzyl alcohol 

Downstream Products

• 881209-04-7 tert-Butyl (S)-1-(3-((S)-2-aminopropyl)phenyl)ethylcarbamate 

Relevant academic research and scientific papers

Comparative approaches toward diamines containing spatially separated homobenzylic and benzylic nitrogen stereocenters

Several synthetic strategies to diamines 1-3 are described. The optimum approach via opening of aziridine afforded 1-3 in 29-60% yield over 3-5 steps. A study on formation of the benzylic stereocenter using Toste's rhenium-catalyzed asymmetric reduction of phosphinyl ketimines was also evaluated and afforded 15 in 92% de.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to compounds having the general structure: (I) and pharmaceutically acceptable salts and hydrates thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple m

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general structure: and pharmaceutically acceptable salts and hydrates thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myelo